Skip to main content

Table 3 Summary the DVH analysis for the reference and the RapidPlan plans for the cohort of validation patients from the clinic C

From: A broad scope knowledge based model for optimization of VMAT in esophageal cancer: validation and assessment of plan quality among different treatment centers

  Objective Reference RapidPlan p
PTV
 Mean [%] 100 % 100.0 ± 0.0 100.0 ± 0.0 -
 D1% [%] <107 % 105.0 ± 1.0 104.8 ± 0.9 -
 V95% [%] >95 % 96.5 ± 2.5 97.1 ± 1.1 -
 St. Dev. [Gy] <5 % 2.5 ± 0.8 2.4 ± 0.8 -
Left lung
 Mean [Gy] <15Gy 11.4 ± 4.7 10.6 ± 4.2 0.01
 V20Gy [%] <20 % 22.4 ± 10.6 18.9 ± 7.2 0.01
Right lung
 Mean [Gy] <15Gy 12.6 ± 5.5 11.9 ± 5.3 0.01
 V20Gy [%] <20 % 24.4 ± 12.3 21.7 ± 11.2 -
Heart
 Mean [Gy] Minimise 15.4 ± 15.1 11.9 ± 11.9 0.06
 V30Gy [%] <30 % 22.7 ± 25.5 16.2 ± 18.7 0.02
Spine
 D1cm3 [Gy] <45Gy 43.3 ± 3.8 43.1 ± 4.4 0.01
Liver
 Mean Minimise 4.9 ± 7.1 4.5 ± 6.4 0.01
Spleen
 Mean [Gy] Minimise 19.7 ± 4.2 13.9 ± 3.5 -
 D1% [Gy] Minimise 45.5 ± 3.2 43.8 ± 4.1 -
Left kidney
 V15Gy [%] <35 % 14.0 ± 16.5 11.5 ± 14.3 -
Right kidney
 V15Gy [%] <35 % 3.8 ± 4.6 3.7 ± 4.9 -
Stomach
 D1% [Gy] Minimise 60.8 ± 0.6 61.5 ± 0.1 -
Small bowel
 Mean [Gy] Minimise 7.7 ± 2.4 6.7 ± 2.3 0.01
 D1% [Gy] <45Gy 39.3 ± 7.0 38.8 ± 6.9 -